Mission Pharmacal for women and babies
This article was originally published in The Tan Sheet
The San Antonio-based firm extends its products marketed to women into OTC lotions with the acquisition of Dr. Smith's Diaper Ointment from innovator Esrubar and marketer Beta Dermaceuticals. Mission Pharmacal did not disclose financial terms of the Aug. 31 deal, which also includes Rash-n-All Ointment. The firm already markets CitraNatal prenatal vitamins and Ferralet 90 iron therapy Rx products, and will give samples of Dr. Smith's products to health care providers who buy its prescription drugs and can recommend the ointment to patients, said company President Neill Walsdorf, Jr. According to Information Resources Inc., Dr. Smith's sales were $1.85 million, or 1.82 percent of the category, in the 52 weeks ending Aug. 9, excluding sales at Wal-Mart, club stores and convenience stores. Desitin leads the baby ointment category at $15.7 million, or 15.37 percent, Chicago-based IRI data show. Mission Pharmacal expects to extend Dr. Smith's Diaper Ointment nationwide in 2010 before growing Rash-n-All sales
You may also be interested in...
Can a false-claims suit be filed if doctors have different opinions about whether a treatment was necessary? The Supreme Court won’t say.
The pharmaceutical industry and other stakeholders have taken part in the launch event for a new initiative intended to tackle issues that have been amplified by the COVID-19 pandemic, such as supply chain resilience and medicine shortages. The project has drawn a mixed response from industry bodies.
Samsung Bioepis has announced that its SB17 proposed biosimilar ustekinumab rival to Janssen’s $7.7bn Stelara brand has moved into Phase I trials.